Press releases.

Press releases 2021

Press releases 2021

Immutep Advances IMP761 Manufacturing

December 16th 2021

Immutep Reports Good Safety from First Five Patients in Triple Combination Therapy Efti Study, Insight-003

December 2nd 2021

Immutep Successfully Completes Recruitment for Phase II TACTI-002 Study of LAG-3 Therapy, Eftilagimod Alpha

November 19th 2021

Immutep Publishes AIPAC, TACTI-002 and TACTI-003 Trial Posters at SITC with Positive New Data for LAG-3 Therapy, Eftilagimod Alpha

November 15th 2021

Immutep Granted Chinese Patent for Eftilagimod Alpha, a Soluble Lag-3 Fusion Protein, in Combination with a PD-1 Pathway Inhibitor

November 15th 2021

Immutep Reports Improved and Statistically Significant Survival Benefit for Three Key Patient Groups in Final Phase IIb AIPAC Study Results in Metastatic Breast Cancer

November 9th 2021

Immutep Announces Publication of AIPAC, TACTI-002 and TACTI-003 Abstracts for SITC 2021 Annual Meeting & AIPAC Global Webcast Details

November 9th 2021

Immutep Granted Chinese Patent for Eftilagimod Alpha, a Soluble Lag-3 Protein, in Combination with a Chemotherapy Agent

November 2nd 2021

Immutep Receives Positive EMA Scientific Advice for Further Clinical Development of Efti in MBC Including Phase III

October 29th 2021

Immutep Quarterly Activities Report

October 28th 2021

Immutep to present Phase II TACTI-002 data at SITC 2021

October 1st 2021

Immutep Receives A$3.4 million R&D Tax Incentive from French Government

September 29th 2021

Immutep to Present at Healthcare Investor Conferences

September 28th 2021

Immutep to Present Final Overall Survival Data From Phase IIb AIPAC as a Late Breaking Poster Presentation at SITC 2021

September 21st 2021

Immutep Completes Recruitment of 2nd line PD-1/PD-L1 refractory NSCLC Patients in TACTI-002

September 1st 2021

Immutep’s Chinese Partner, Eoc Pharma, Expands Efti Trial Pipeline

August 31st 2021

Immutep Announces Chinese Patent Grant for LAG-3 Antagonist Antibody LAG525

August 27th 2021

Immutep Reports Dosing of First Patient for Triple Combination (efti + anti-PD-1 + chemo) in INSIGHT-003

August 5th 2021

Immutep Quarterly Activities Report

July 13th 2021

Immutep receives FDA and IRB approval in the US for Phase IIb TACTI-003 trial in HNSCC

July 6th 2021

Immutep Completes a A$60 Million Placement to Expand its Clinical Development and Manufacturing Program into Late-Stage Settings

June 21st 2021

Immutep to Evaluate Efti in Triple Combination Therapy Phase I Study with Chemotherapy and an anti-PD-1 Therapy

June 21st 2021

Immutep Reveals a New anti-LAG-3 Research Program

June 8th 2021

Immutep Reports Positive Data from its TACTI-002 Phase II Study of LAG-3 Therapy, Efti, at ASCO 2021

June 4th 2021

Immutep Reports Positive Final Data from the INSIGHT-004 Phase I Study of LAG-3 Therapy, Efti, at ASCO 2021

June 4th 2021

Immutep Secures Second European Patent For Eftilagimod Alpha, A Soluble LAG-3 Protein, In Combination With A PD-1 Pathway Inhibitor

June 2nd 2021

Immutep Enters into a New Collaboration with Merck KGaA, Darmstadt, Germany for LAG-3 Therapy, Efti

June 1st 2021

Immutep Granted Chinese Patent for Eftilagimod Alpha in Chemo-Immunotherapy Combination

May 26th 2021

Immutep to Present at the Jefferies Virtual Healthcare Conference

May 25th 2021

Immutep Announces Publication of TACTI-002 and INSIGHT-004 Abstracts for ASCO 2021 Annual Meeting

May 20th 2021

Immutep Operational Update

May 7th 2021

Immutep To Announce New TACTI-002 and INSIGHT-004 Data in Poster Presentations and Discussion at the ASCO 2021 Annual Meeting

April 28th 2021

Immutep Quarterly Activities Report

April 19th 2021

Immutep Receives A$1,155,055 R&D Tax Incentive

April 16th 2021

Immutep Achieves Fast Track Designation From US FDA For Efti, A Soluble Lag-3 Protein, In First Line Recurrent/Metastatic Head & Neck Cancer

April 8th 2021

Immutep Announces European Patent Grant For LAG525 Antibody In Combination Therapy

April 7th 2021

Immutep To Participate In A Fireside Chat At The Inaugural M Vest And Maxim Group Emerging Growth Virtual Conference

March 17th 2021

Immutep Enters Second Collaboration with MSD for a New Randomised Phase IIB Trial in Head and Neck Cancer

March 16th 2021

Immutep Secures Second United States Patent Grant For Eftilagimod Alpha In Combination With A PD-1 Pathway Inhibitor

March 9th 2021

Immutep Expands Part B of TACTI-002 Study

March 5th 2021

Immutep Announces Advancement Of Phase II Trial For Eftilagimod Alpha In Covid-19 Patients To Randomised Portion Of The Study

January 27th 2021

Immutep Quarterly Activities Report

January 21st 2021

Ulcerative Colitis Phase II Study of GSK2831781 Discontinued

January 21st 2021

Immutep Completes Recruitment of Head and Neck Cancer Patients of Phase II TACTI-002 Study

January 6th 2021